로그인 회원가입
icon_bulk_order대량 주문 Acrobiosystems for English
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Kits > DLL3 > CEA-B049

Human DLL3 ELISA Kit

For research use only.
Recommended Hot Products:

Order Now

    Product Overview
    Human DLL3 ELISA Kit is a ready-to-use immunoassay kit, specifically designed to quantitate natural and recombinant human DLL3 that is present in biological samples, such as human serum, plasma, and cell culture supernatants. Our ELISA Kit provides several benefits:
    1. Fully validation in biologic samples for detection range, sensitivity, inter- and intra-plate CV, recovery, dilution linearity, specificity, and matrix effects to ensure reliable results according to ICH M10 guideline.
    2. High-quality antibody pairs and protein standards, along with rigorous quality control, to guarantee consistent results across different batches.
    3. Simplified and straightforward protocols and ready-to-use reagents to save assay time.
  • Application

    The kit is developed for quantitative detection of natural and recombinant human DLL3 in serum, plasma and cell culture supernatants.

    It is for research use only.

  • Workflow
     DLL3 Workflow
  • Product Specifications
    Assay TypeSandwich-ELISA
    AnalyteDLL3
    Format96-wells plate breakable into 12 x 8 wells strips
    ReactivityHuman
    Sensitivity<54.69 pg/mL
    Assay Time2.75 hr
    Sample volume100 μL
    Range54.69 pg/mL-3500 pg/mL
    Sample TypeFor the quantitative determination of human DLL3 in serum, plasma and cell supernatant.

    Elevate your research experience with our Cytokine/Biomarker Detection Kits, where accuracy, reliability, and ease of use are converging to deliver exceptional results.

  • Storage
    Keep the unopened kit stored at 2-8 °C. Avoid using the kit beyond its expiration date. The opened kit should be stored per components table. The shelf life is 30 days from the date of opening.
Typical Data Please refer to DS document for the assay protocol.
 DLL3 TYPICAL DATA

For each experiment, a standard curve needs to be set for each microplate, and the specific OD value may vary depending on different laboratories, testers, or equipment. The following example data is for reference only. The sample concentration was cal-culated based on the results of the standard curve. The minimum detectable con-centration of DLL3 is less than 54.69 pg/mL.

Validation
Dilution Linearity

High concentrations of human DLL3 serum samples were diluted with 1:2, 1:4, 1:8, 1:16 ratios for gradient dilution to evaluate the linearity of the assay. In the serum samples, the average detection rate of DLL3 was 96.1%.

 DLL3 DILUTION LINEARITY
Intra-Assay Statistics

Ten replicates of each of four samples containing different DLL3 concentrations were tested in one assay. Acceptable criteria: CV<10%.

 DLL3 INTRA-ASSAY STATISTICS
Inter-Assay Statistics

Five samples containing different concentrations of DLL3 were tested in the independent assays. Acceptable criteria: CV<15%.

 DLL3 INTER-ASSAY STATISTICS
Recovery

DLL3 was spiked into three human serum samples, and then analyzed. The average re-covery of DLL3 for serum samples is 90.5%.

 DLL3 RECOVERY
Materials Provided
IDComponentsSize
CEA049-C01Pre-coated Anti-DLL3 Antibody Microplate1 plate
CEA049-C02Human DLL3 Standard20 μg×2
CEA049-C03Biotin-Anti-DLL3 Antibody Con. Solution300 μL
CEA049-C042×Biotin-Antibody Dilution Buffer8 mL
CEA049-C05Streptavidin-HRP Con. Solution500 μL
CEA049-C06Streptavidin-HRP Dilution Buffer15 mL
CEA049-C0720×Washing Buffer50 mL
CEA049-C08Sample Dilution Buffer15 mL×2
CEA049-C09Substrate Solution12 mL
CEA049-C10Stop Solution6 mL
  • Clinical and Translational Updates

Comments (0)

Drug Candidate Licensing

more

Drug Development Status

  • Number of Launched Drugs:0 Details
  • Number of Drugs in Clinical Trials:11 Details
  • Latest Research Phase:NDA/BLA

Datasheet & Documentation

Related Products

New Product Launch

Questions & Comments

This web search service is supported by Google Inc.

totop